# Minerva Neurosciences

Minerva Neurosciences is an Asset Manager based in Waltham, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Waltham, United States
- **Region:** North America
- **Address:** Waltham, MA, United States
- **Founded:** 2007
- **Assets under management:** Undisclosed
- **Website:** minervaneurosciences.com

## Regulatory record

- **Reports private funds:** No

## About

Minerva Neurosciences was founded in 2007 and took a distinct corporate path, becoming a clinical-stage biopharmaceutical company focused on central nervous system disorders. The firm structured itself as a publicly traded entity rather than a private family office, with Dr. Remy Luthringer serving as its long-time CEO and later Executive Chairman. Its sole purpose was developing drugs for conditions like schizophrenia, major depressive disorder, and Parkinson's disease, licensed from Mitsubishi Tanabe Pharma and other research institutions. The firm's strategy concentrated on a single high-stakes asset: roluperidone, a negative symptom schizophrenia treatment. This narrow deployment meant the entire public-market valuation tracked the FDA approval process. The company advanced a portfolio of three other CNS drug candidates alongside roluperidone, covering MIN-117 for major depressive disorder and MIN-301 for Parkinson's disease, but none reached the pivotal-stage prominence of the lead program. Its geographic focus was on US regulatory approval and clinical trial sites across North America and Europe. By 2022, Minerva employed a lean team of roughly a dozen full-time staff, typical for a development-stage biotech with no approved products. Its operations were entirely virtualized or based out of Waltham, Massachusetts. A critical operational event occurred in August 2022: the FDA issued a complete response letter for roluperidone, declining to approve the drug and sending the company's stock down over 60% in a single day (per Endpoints News, August 2022). The firm entered a wind-down evaluation period immediately following that decision. The company's structural differentiator was its all-or-nothing approach as a single-asset public biotech. Unlike diversified family offices or multi-asset managers, Minerva's fate was binary — tied to an FDA binary event. This structure, common in early-stage biotech but rare among standard family-office profiles, meant the firm operated more like a publicly traded options contract on a clinical trial readout than a perpetual capital vehicle.

## Sectors

- Digital Health
- Healthcare Services

## People

- Remy Luthringer — Executive Chairman and former CEO

## Questions

### What happened to Minerva's lead drug candidate, roluperidone?

Roluperidone, a treatment for negative symptoms of schizophrenia, received a complete response letter from the FDA in August 2022. The agency declined to approve the drug, stating the company had not provided substantial evidence of effectiveness. This rejection triggered a severe stock decline and forced the company to evaluate its ongoing viability as a going concern (per Endpoints News, August 2022).

### Who founded Minerva Neurosciences and what was its original mandate?

Minerva Neurosciences was co-founded in 2007 by Dr. Remy Luthringer and others to develop CNS therapies, with an initial focus on licensing programs from Mitsubishi Tanabe Pharma. Dr. Luthringer, a neuropsychiatry researcher, led the company as CEO until transitioning to Executive Chairman. The mandate was strictly clinical-stage drug development, not capital management or multi-asset investing.

### Did Minerva have any other assets besides roluperidone?

The company's pipeline included MIN-117 (a serotonin receptor modulator for major depressive disorder), MIN-301 (a soluble erythropoietin receptor for Parkinson's disease), and earlier-stage compounds. However, none of these reached the advanced clinical stage of roluperidone, and the company's public disclosures consistently framed the lead CNS asset as its primary value driver.

## Related profiles

- [Entrada Therapeutics](https://altss.com/profile/entrada-therapeutics-inc)
- [Stratus Properties](https://altss.com/profile/stratus-properties-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/minerva-neurosciences-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology